The Effects of Aspirin and Acetaminophen on the Stomach in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

94 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-31

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aspirin is a medication commonly used to relieve minor pains. Aspirin has also been used to prevent heart attacks and strokes. Aspirin, however, can also cause damage to the stomach and/or intestinal lining leading to the development of erosions ("small sores") and/or ulcers ("large sores"). Erosions may cause bleeding ("bleeding ulcers") and/or perforations ("holes in the stomach"). Acetaminophen, often referred by the brand name, Tylenol, is also used to treat minor pains but is not commonly recognized to cause damage to the stomach lining.

Many patients often take both of these medications together. While the effects on the stomach lining of each medication, when used alone, are known, the effects of both medications, when used together, are not.

The purpose of this study is to show whether or not the collective effects of both aspirin and acetaminophen, when used together, increase the damage on the stomach lining when compared to either medication alone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mechanisms of Action of Acetaminophen

NCT00646906

Myocardial Infarction Arthritis

COMPLETED NA

Dose-related Effect of Aspirin on Laboratory-defined Acetylsalicylic Acid Resistance and Clinical Outcome After Coronary Stenting

NCT00966485

Coronary Stenting

COMPLETED NA

Aspirin in Patients With Myocardial Infarction and Thrombocytopenia

NCT00501345

Thrombocytopenia Myocardial Infarction

TERMINATED PHASE3

Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting

NCT01276691

Cardiovascular Risk Factor C.Medical Procedure; Vascular, Functional or Late Electrolyte and Fluid Balance Conditions

COMPLETED PHASE4

The Effect of Low Dose Aspirin on the Pharmacokinetics of Methotrexate

NCT00464997

Rheumatoid Arthritis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Low dose aspirin is used for the primary and secondary prevention of cardiovascular thromboembolic events. As a non-selective inhibitor of cyclooxygenase, aspirin use results in irreversible COX-1 inhibition leading to impaired platelet aggregation. However, aspirin also inhibits COX-1 activity in the gastric mucosa by suppressing the synthesis of protective prostaglandins. In doing so, this creates a state of propensity for the development of aspirin-associated gastrointestinal ulcers and ulcer complications.

A high proportion of aspirin users also require concomitant use of anti-inflammatory medications for the treatment of pain and arthritis. However, evidence suggests that the risk of developing gastroduodenal ulcers and ulcer complications is significantly increased when aspirin is co-administered with other nonselective NSAIDs. In a previous study, concomitant aspirin (325 mg daily) in healthy subjects taking naproxen (500mg bid) was associated with endoscopic ulcer rates of 27.3% as compared to aspirin alone (7.6%). In a separate and independent trial of similar design, patients using 81 mg of aspirin in conjunction with daily naproxen also resulted in a higher incidence of gastric and duodenal ulcers than aspirin therapy alone. Beyond endoscopic ulcer rates, the risk of upper gastrointestinal hemorrhage has been reported to be substantially increased with concurrent administration of low-dose aspirin with nonselective NSAIDS. These data suggest that the gastrointestinal toxicity of combined aspirin with other NSAIDs may be more than additive.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Acetaminophen - 4 grams per day + Placebo

Group Type ACTIVE_COMPARATOR

Acetaminophen - 4 grams per day + Placebo

Intervention Type DRUG

Acetaminophen - 4 grams per day + Placebo

2

Aspirin - 325 mg per day + Placebo

Group Type ACTIVE_COMPARATOR

Aspirin - 325 mg per day + Placebo

Intervention Type DRUG

Aspirin - 325 mg per day + Placebo

3

Acetaminophen 4 gram per day + Aspirin 325 mg per day

Group Type EXPERIMENTAL

Acetaminophen 4 gram per day + Aspirin 325 mg per day

Intervention Type DRUG

Acetaminophen 4 gram per day + Aspirin 325 mg per day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acetaminophen - 4 grams per day + Placebo

Intervention Type DRUG

Aspirin - 325 mg per day + Placebo

Intervention Type DRUG

Acetaminophen 4 gram per day + Aspirin 325 mg per day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Be a cooperative, healthy male or female between the ages of 18-75 inclusive.
2. Have a physical examination which reveals no clinically significant abnormalities at the screening visit.
3. Have fewer than 6 gastric or duodenal erosions visible on nasal endoscopy at Visit 2.
4. If the subject is female and of childbearing potential, she has been using effective contraception since the last date of her menses, will continue to use effective contraception during the study period, is not breast-feeding or lactating at screening and has had a negative urine pregnancy test at screening. Women who have been post-menopausal for less than 2 years will also require a urine pregnancy test at screening.
5. Have provided written informed consent prior for admission to this study.
6. H. pylori negative serologic exam prior to baseline nasal EGD.

Exclusion Criteria

1. Active GI disease (e.g. IBD), or a history of GI ulcers or bleeding
2. History of gastric or intestinal surgery
3. Use of ASA, NSAIDs, coxibs, or acetaminophen at any dose within 2 weeks prior to the randomization visit of the study.
4. Positive FOBT at baseline.
5. Use of over-the-counter or prescription: sucralfate, antacids, H2-receptor antagonists, misoprostol, or proton pump inhibitors 4 weeks prior to enrollment and/or during the study
6. A known allergy to the topical anesthetic, lidocaine.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes